GSK3359609

Research code: GSK3359609
Research name: Randomised double-blind phase II/III adaptive research evaluating GSK3359609 or placebo in combination with pembrolizumab for first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck with PD-L1 expression.
Indication: head and neck cancer
Principal researcher: Ewa Chmielowska, MD, PhD